<DOC>
	<DOCNO>NCT01436123</DOCNO>
	<brief_summary>Intensive therapy rosuvastatin 40 mg ApoA-I Milano reduce total atheroma volume ( TAV ) 6.38 14.1 mm3 respectively . Our previous bench study PLASMONICS NANOM First-in-Man trial document TAV reduction unprecedented 79.4 60.3 mm3 respectively high level safety feasibility . The complete randomized two arm ( 1:1 ) study ( NANOM-PCI ) parallel assignment ( n=62 ) assess ( NCT01436123 ) safety feasibility delivery technique nanoparticles ( NP ) use micro-injection catheter ( intravascular intramural injection allogeneous stem cell carry NP MSCT- , IVUS- OCT-guided mapping vessel ) , plasmonic photothermal therapy atherosclerosis combine stenting ( Nano group , n=32 ) versus stenting Xience V cage ( Stenting group , n=30 ) . The primary outcome TAV 12 month . The mean reduction TAV 12 month Nano group -84.1 mm3 ( 95 % CI : SD 28.3 ; min -52.4 mm3 , max -99.1 mm3 ; p &lt; 0.05 ) versus +12.4 mm3 case stenting ( p &lt; 0.05 group ) . 42/62 patient ( 68 % ) Nano group pass Glagov threshold 40 % plaque burden mean plaque burden ( PB ) 36.2 % ( 95 % CI : SD 9.3 % , min 30.9 % , max 44.5 % ) . The increase minimal lumen diameter 61.2 63.3 % 12 month follow group respectively . The serial assessment VH-IVUS show significant decrease 12 month dense calcium area , fibrous fibro-fatty tissue fulminant necrosis due thermolysis Nano-group , whereas increase fibrous fibro-fatty component stenting arm . We document 2 v 3 case definite thrombosis 3 v 5 case target lesion revascularization group respectively . The analysis event-free survival ongoing clinical follow-up show significantly low risk cardiovascular death Nano group compare conventional stenting ( 93.4 % vs 86.7 % ; p &lt; 0.05 ) . Plasmonic resonance-mediated therapy use noble-metal NP associate significant regression coronary atherosclerosis . Tested delivery approach acceptable safety efficacy atheroregression 40 % PB . The investigator hypothesize multistep approach use stent acute care unit , subsequent transcatheter micro-injection nanoparticles resolve atherosclerosis , stop regress atherogenesis , remodulate even rejuvenate artery . Stem cell patch good carrier nanoparticles well high-effective metabolic vector ( paracrine-like regulation alive cell via bioactive product cell lysis detonation nanoparticles ) treatment plaque site . Gold nanoparticles silica-iron oxide shell promise high-energy plasmonic photothermic burn melt effect near-infrared laser irradiation onto lesion . Thus investigator expect complex two-side effect plaque protect lumen adventitia . Novel discoveries atherogenesis , development nanobiotechnologies potentials management atherosclerosis lead u quest new approach . The investigator still really effectively treat atherosclerosis . The investigator management symptomatic , lipid-pool inflammation-oriented ! The investigator manage non-organic part ( mineral deposit , calcify necrotic core , partially collagen fibrotic tissue ) total plaque volume Surgery invasive procedure focus blood flow restoration ( manipulate form plaque ) + concern clinical technical restriction ( incl . alien body - stent ) + risk restenosis subacute 'fatal ' in-stent atherothrombosis + graft survival/ occlusion + surgery-related complication High rate short- long-term complication readmission . Regression atherosclerosis fact still dream . The investigator offer alternative stenting may cardiac artery bypass surgery ( CABG ) . Our approach really allow rejuvenate artery , Plasmonic photothermal therapy ( PPTT ) burn plaque , stem cell bioengineered structure promise restoration vessel wall . Our personal previous data show PPTT 1.6-fold reduce volume plaque optimal long-term result subset use SPCs delivery approach . The optimal delivery system NPs plaque on-artery bioengineered patch ferro-magnetic approach .</brief_summary>
	<brief_title>Plasmonic Photothermal Stem Cell Therapy Atherosclerosis Versus Stenting</brief_title>
	<detailed_description>Nanoparticles ( NPs ) quite safe organism entire kinetics mostly unknown . The dangerous approach low level efficacy safety delivery NPs microbubbles . SP+ mesenchymal SPCs similar efficacy local delivery system lot beneficial property anti-inflammative , anti-apoptotic , multi-metabolic effect lead plaque degradation artery rejuvenation . Thus , nanoburning challenge technique demolish reverse plaque especially combination stem cell technology promise functional restoration vessel wall alternative stenting . Altering general strategy investigator generally offer : 1 . The investigator n't need therapy harvest stem cell ( effective , provocative ) ; investigator manage host resident stem cell site [ local in-artery infusion ] growth factor , cytokine [ systemic potentiation , risk side effect adverse event high ] . 2 . Regular intravenous systemic therapy modify BM ( bone marrow ) , circulate progenitor , iPS ( induced pluripotent ) stem cell might beneficial prevention disease , rejuvenation tissue organs - system whole compromise [ investigator store stem cell individual use cell therapy bioengineering ] . 3 . The best way - development bioengineered construction life transplant bioartificial organ request . 4 . Multi-step invasive treatment atherosclerosis - ( 1 ) biodegradable stenting ACU ( acute care unit ) , preventively , restenosis acute atherothrombosis risk profile , ( 2 ) regular systemic local stem cell therapy , cytokine , ( 3 ) on-artery MSCs ( mesenchymal stem cell ) -related bioengineered patch silica-gold iron-bearing NPs [ SCs ( stem cell ) carrier NPs transduction hand magnetic field local elimination plaque , subsequent rejuvenation artery wall . Our new approach , challenge modern therapy atherosclerosis include : 1 . BIODEGRADABLE STENTS - 6-24 month period soft short-term antithrombotic therapy ( resolve concern stenosis/ lumen + steered remodeling ) ; hemorrhage , alien metal body , concern CABG , minimal inflammation 2 . INTRAVENOUS NON-SPECIFIC SYSTEMIC STEM CELL THERAPY - stenting - launch repair effect vessel + beneficial effect ischemic injured tissue 3 . ON-ARTERY BIOENGINEERED PATCH transplantation NPs MICRO-INFUSION stem cell bear NP - grown MSCs NPs ( bovine pericardium scaffold ) ; 3-6 week grow thin structure ( recover cell stenting ) , multi-effects due migration SCs + bioactive product lysis 4 . PLASMONIC PHOTOTHERMAL THERAPY - 'melting ' 'burning ' effect - direct degradation + bioactive product stem cell ' lysis + migration SCs patch Potential expect disadvantage approach : Necessity special precise delivery technique . Lost function artery - irreparable pro-fibrotic pro-inflammative damage - necessity another clinical approach restoration tissue ( may stem cell ) . Threat acute fatal atherothrombosis due rupture ( vulnerable ) plaque - verification optimal antithrombotic therapy . Can treat non-organic part plaque - necessity special therapy mineral deposit , calcify necrotic core , fibrotic site - solution use stem cell . Harm potent detrimental adverse effect - vapor bubbling ( boil cytoplasm ECM subsequent lysis cell , provocation pro-apoptotic cascade ) , acoustic shock wave due plasma-generated laser-related detonation nanoshells tissue - need regenerative therapy ( type SCs , condition way transplantation ; Culturing ? Sorting ? ) . Erratic ( unsteered ) heat - surround tissue site interest achieve temperature 38-39Â° . But site burn final temperature 50-180 C ( cauterization/ searing/ melt effect ) consequent pro-fibrotic effect - need regenerative therapy clarification energy option .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Multivessel coronary artery disease without indication CABG Stable angina indication preventive PCI NSTEMI ( primary PCI late comer ) &lt; = &gt; 12 hr STEMI keep EF &gt; 50 % ( comer ) Rescue PCI Vessel size 2.34.0 mm NYHA IIIII functional class HF De novo treatment = history PCI CABG Atherosclerosis proximal leave anterior descend artery &lt; 50 % stenosis Treated hypertension Signed write informed consent History MI History CABG PCI Indications CABG Contraindications CABG , PCI History unstable angina , coronary artery syndrome History arrhythmias History stroke NYHA I , IV functional class HF Diabetes ( fast glucose &gt; 7.0 mM/L ) Untreated hypertension Asthma Participation druginvestigations previous 60 day Pregnancy Intolerance limus drug , aspirin , clopidogrel , aspirin , metal polymer stent nanoparticles Need chronic treatment antivitamin K drug Impossibility clinical followup</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Plasmonic Photothermal Therapy</keyword>
	<keyword>Nanoparticles</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Bioengineering</keyword>
	<keyword>Biodegradable stenting</keyword>
	<keyword>Repair disease</keyword>
</DOC>